{"id":"intravenous-iv-ganciclovir","safety":{"commonSideEffects":[{"rate":"15-30","effect":"Neutropenia"},{"rate":"5-15","effect":"Thrombocytopenia"},{"rate":"5-10","effect":"Anemia"},{"rate":"10-15","effect":"Renal impairment"},{"rate":"5-10","effect":"Neurotoxicity (confusion, hallucinations)"},{"rate":null,"effect":"Phlebitis at injection site"}]},"_chembl":{"chemblId":"CHEMBL1200850","moleculeType":"Small molecule","molecularWeight":"277.22"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ganciclovir is phosphorylated by viral kinases (or cellular kinases in CMV-infected cells) to form active triphosphate metabolites that competitively inhibit viral DNA polymerase and cause chain termination during viral DNA synthesis. This selective activity against CMV and other herpesviruses makes it effective for treating serious viral infections in immunocompromised patients.","oneSentence":"Ganciclovir is a nucleoside analog that inhibits viral DNA polymerase, preventing replication of herpes viruses, particularly cytomegalovirus (CMV).","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:49:52.933Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cytomegalovirus (CMV) retinitis in immunocompromised patients"},{"name":"CMV disease prevention in transplant recipients"},{"name":"Herpes simplex virus infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT04706507","phase":"PHASE3","title":"Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis","status":"TERMINATED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2021-06-29","conditions":"Acute Respiratory Failure","enrollment":205},{"nctId":"NCT05166577","phase":"PHASE1","title":"Nanatinostat Plus Valganciclovir in Advanced EBV+ Solid Tumors and in Combination With Pembrolizumab in EBV+ RM-NPC","status":"TERMINATED","sponsor":"Viracta Therapeutics, Inc.","startDate":"2021-10-08","conditions":"Nasopharyngeal Carcinoma, EBV-Related Gastric Carcinoma, EBV-Related Leiomyosarcoma","enrollment":26},{"nctId":"NCT03532035","phase":"PHASE2","title":"Open Label Study of IV Brincidofovir in Adult Transplant Recipients With Adenovirus Viremia","status":"WITHDRAWN","sponsor":"Jazz Pharmaceuticals","startDate":"2018-12-15","conditions":"Adenovirus","enrollment":""},{"nctId":"NCT04278547","phase":"PHASE4","title":"Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response","status":"UNKNOWN","sponsor":"Hospital Universitari de Bellvitge","startDate":"2020-06-12","conditions":"Heart Transplant Infection, CMV Infection","enrollment":188},{"nctId":"NCT02188719","phase":"PHASE1","title":"Donor-Alloantigen-Reactive Regulatory T Cell (darTregs) in Liver Transplantation","status":"TERMINATED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-12-17","conditions":"Liver Transplantation","enrollment":15},{"nctId":"NCT00372229","phase":"PHASE3","title":"A Study of Valcyte (Valganciclovir) CMV Prophylaxis After Renal Transplantation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2006-05","conditions":"Cytomegalovirus Infections","enrollment":299},{"nctId":"NCT01335932","phase":"PHASE2","title":"Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2011-03-10","conditions":"Acute Lung Injury, Acute Respiratory Distress Syndrome, Respiratory Failure","enrollment":160},{"nctId":"NCT00530218","phase":"PHASE2","title":"Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"1999-03","conditions":"Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Leukemia, Lymphoma","enrollment":61},{"nctId":"NCT00431353","phase":"PHASE4","title":"VICTOR Study - A Study of Valcyte (Valganciclovir po) Compared to Ganciclovir iv in Patients With Cytomegalovirus (CMV) Disease Who Are Solid Organ Transplant Recipients","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2004-04","conditions":"Cytomegalovirus Infections","enrollment":325},{"nctId":"NCT00000143","phase":"PHASE3","title":"Studies of Ocular Complications of AIDS (SOCA)--Ganciclovir-Cidofovir CMV Retinitis Trial (GCCRT)","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"1997-05","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":61},{"nctId":"NCT00241345","phase":"PHASE3","title":"Trial of Preemptive Treatment With Oral Valganciclovir Compared With Intravenous (IV) Ganciclovir for Cytomegalovirus Infection After Bone Marrow or Peripheral Blood Stem Cell Transplant","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2004-06","conditions":"Cytomegalovirus Infections","enrollment":39},{"nctId":"NCT00264368","phase":"PHASE4","title":"Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy","status":"TERMINATED","sponsor":"University of Oslo School of Pharmacy","startDate":"2005-12","conditions":"Acute Renal Failure, Cytomegalovirus Infections, Multi Organ Failure","enrollment":6},{"nctId":"NCT00017784","phase":"PHASE3","title":"Valganciclovir in Patients With CMV Retinitis and AIDS Who Cannot Take Drugs by Injection","status":"UNKNOWN","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Cytomegalovirus Retinitis, HIV Infections","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":42,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"intravenous (IV) ganciclovir","genericName":"intravenous (IV) ganciclovir","companyName":"University of Oslo School of Pharmacy","companyId":"university-of-oslo-school-of-pharmacy","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ganciclovir is a nucleoside analog that inhibits viral DNA polymerase, preventing replication of herpes viruses, particularly cytomegalovirus (CMV). Used for Cytomegalovirus (CMV) retinitis in immunocompromised patients, CMV disease prevention in transplant recipients, Herpes simplex virus infections in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}